These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 25623393)

  • 21. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.
    Kavanaugh A; Husni ME; Harrison DD; Kim L; Lo KH; Leu JH; Hsia EC
    Arthritis Rheumatol; 2017 Nov; 69(11):2151-2161. PubMed ID: 28805045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS; Kay J; Matteson EL; Landewé R; Hsia EC; Xu S; Zhou Y; Doyle MK
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical response to golimumab in rheumatoid arthritis patients who were receiving etanercept or adalimumab: results of a multicenter active treatment study.
    Huffstutter JE; Kafka S; Brent LH; Matucci-Cerinic M; Tang KL; Chevrier M; Sprabery T; DeHoratius RJ
    Curr Med Res Opin; 2017 Apr; 33(4):657-666. PubMed ID: 28035867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
    Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
    Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E; Heijde Dv; Mason D; Landewé R; Vollenhoven RV; Combe B; Emery P; Strand V; Mease P; Desai C; Pavelka K
    Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
    Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
    J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial.
    Kavanaugh A; van der Heijde D; McInnes IB; Mease P; Krueger GG; Gladman DD; Gómez-Reino J; Papp K; Baratelle A; Xu W; Mudivarthy S; Mack M; Rahman MU; Xu Z; Zrubek J; Beutler A
    Arthritis Rheum; 2012 Aug; 64(8):2504-17. PubMed ID: 22378566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy, radiographic, and safety results of golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior therapy with disease-modifying antirheumatic drugs: Final results of the GO-MONO trial through week 120.
    Takeuchi T; Harigai M; Tanaka Y; Yamanaka H; Ishiguro N; Yamamoto K; Miyasaka N; Koike T; Ukyo Y; Ishii Y; Yoshinari T; Baker D;
    Mod Rheumatol; 2018 Sep; 28(5):770-779. PubMed ID: 29219638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial.
    Smolen JS; Van Der Heijde DM; St Clair EW; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Schiff M; Baker D; Han C; Han J; Bala M;
    Arthritis Rheum; 2006 Mar; 54(3):702-10. PubMed ID: 16508926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
    Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
    Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.
    Emery P; Fleischmann R; van der Heijde D; Keystone EC; Genovese MC; Conaghan PG; Hsia EC; Xu W; Baratelle A; Beutler A; Rahman MU
    Arthritis Rheum; 2011 May; 63(5):1200-10. PubMed ID: 21305524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial.
    Rigby W; Tony HP; Oelke K; Combe B; Laster A; von Muhlen CA; Fisheleva E; Martin C; Travers H; Dummer W
    Arthritis Rheum; 2012 Feb; 64(2):350-9. PubMed ID: 21905001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.
    Kay J; Matteson EL; Dasgupta B; Nash P; Durez P; Hall S; Hsia EC; Han J; Wagner C; Xu Z; Visvanathan S; Rahman MU
    Arthritis Rheum; 2008 Apr; 58(4):964-75. PubMed ID: 18383539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.
    Keystone E; Genovese MC; Klareskog L; Hsia EC; Hall S; Miranda PC; Pazdur J; Bae SC; Palmer W; Xu S; Rahman MU
    Ann Rheum Dis; 2010 Jun; 69(6):1129-35. PubMed ID: 20444749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.